Core Viewpoint - The Organon class action lawsuit alleges that the company and its executives made misleading statements regarding capital allocation and dividend payouts, leading to significant financial losses for investors [1][4]. Group 1: Lawsuit Details - The lawsuit, titled Hauser v. Organon & Co., seeks to represent purchasers of Organon securities and claims violations of the Securities Exchange Act of 1934 [1]. - Allegations include the concealment of material information about Organon's capital allocation priorities and a drastic reduction of the quarterly dividend payout by over 70% [4]. - On May 1, 2025, Organon announced a reduction in its dividend payout from $0.28 to $0.02, resulting in a stock price drop of more than 27% [5]. Group 2: Lead Plaintiff Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Organon securities during the class period to seek appointment as lead plaintiff [6]. - The lead plaintiff represents the interests of all class members and can select a law firm for litigation [6]. Group 3: Company Background - Organon develops health solutions through prescription therapies and medical devices [3]. - Robbins Geller Rudman & Dowd LLP, the law firm handling the case, is recognized for securing substantial monetary relief for investors in securities fraud cases [7].

Core Viewpoint - A lawsuit has been filed against Organon & Co. and its senior executives for potential violations of federal securities laws, particularly related to misleading statements about dividend policies following a significant acquisition [1][2][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the District of New Jersey, under the case caption Hauser v. Organon & Co., et al., No. 25-cv-05322, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [2]. - Investors have until July 22, 2025, to request to be appointed to lead the case [2]. Group 2: Company Background and Acquisition - Organon is a global healthcare company focused on women's health, known for rewarding shareholders with dividends [3]. - In October 2024, Organon completed a $1.2 billion acquisition of Dermavant, a biopharmaceutical company, which increased its debt [3]. Group 3: Dividend Policy and Stock Performance - Following the acquisition, Organon assured investors it would maintain its dividend, which was stated as its "1 capital allocation priority" [3]. - On May 1, 2025, Organon announced a drastic cut in its dividend payout from $0.28 per share to $0.02 per share, citing a shift in capital allocation priorities towards debt reduction [4]. - This announcement led to a significant decline in Organon's stock price, dropping approximately 27% from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025 [4].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Organon & Co. regarding a class action lawsuit due to allegations of misleading statements and a significant reduction in quarterly dividends, which led to a sharp decline in the company's stock price [1][2]. Group 1: Allegations and Impact - The class period for the allegations is from October 31, 2024, to April 30, 2025 [2]. - Defendants allegedly provided overly positive statements while concealing material adverse facts about Organon's capital allocation priorities, particularly regarding debt reduction after the acquisition of Dermavant [2]. - Following the revelation of these issues, Organon's stock price plummeted from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025, marking a decline of over 27% in just one day [2]. Group 2: Class Action Details - Shareholders are encouraged to register for the class action by the deadline of July 22, 2025, to potentially become lead plaintiffs [3]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the case lifecycle [3]. - Participation in the case incurs no cost or obligation for shareholders [3]. Group 3: Law Firm's Mission - The Gross Law Firm aims to protect investors' rights against deceit, fraud, and illegal business practices, emphasizing the importance of responsible corporate behavior [4]. - The firm seeks recovery for investors who suffered losses due to misleading statements or omissions that artificially inflated stock prices [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Organon & Co. securities during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - The class period for the Organon securities lawsuit is from October 31, 2024, to April 30, 2025, inclusive [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A lead plaintiff must file a motion with the court by July 22, 2025, to represent other class members [2]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions [3]. - Rosen Law Firm has a history of significant settlements, including the largest securities class action settlement against a Chinese company at the time [3]. - The firm has consistently ranked in the top 4 for securities class action settlements since 2013 and recovered hundreds of millions for investors [3]. Group 3: Case Allegations - The lawsuit alleges that Organon's defendants made misleading statements about the company's priorities, particularly regarding capital allocation and dividend payments [4]. - It is claimed that the defendants concealed the importance of debt reduction following the acquisition of Dermavant, leading to a 70% decrease in the regular quarterly dividend [4]. - The lawsuit asserts that investors suffered damages when the true information was revealed [4].

Core Viewpoint - Investors in Organon & Co. have the opportunity to lead a securities fraud class action lawsuit due to undisclosed information regarding dividend payouts and debt reduction strategies [1][2]. Summary by Relevant Sections Lawsuit Details - The lawsuit alleges that from October 31, 2024, to April 30, 2025, Organon failed to disclose that its reported commitment to dividend payouts was undermined by a new debt reduction strategy, resulting in a more than 70% decrease in quarterly dividends [2]. - It is claimed that Organon prioritized debt reduction following its acquisition of Dermavant, which was not communicated to investors [2]. - The positive statements made by the company regarding its business and prospects were misleading and lacked a reasonable basis during the relevant period [2]. Participation Information - Investors who suffered losses in Organon & Co. are encouraged to participate in the ongoing securities fraud lawsuit before the lead plaintiff deadline of July 22, 2025 [2]. - Interested parties can contact the Law Offices of Frank R. Cruz for more information or to learn about their rights regarding this matter [3][4].

Core Viewpoint - A class action securities lawsuit has been filed against Organon & Co. due to alleged securities fraud that affected investors between October 31, 2024, and April 30, 2025 [1][2] Group 1: Lawsuit Details - The lawsuit claims that Organon's management made overly positive statements while concealing material adverse facts about the company's capital allocation priorities, particularly regarding its debt reduction strategy after acquiring Dermavant [2] - Following the revelation of a 70% decrease in the regular quarterly dividend, Organon's stock price plummeted from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025, marking a decline of over 27% in just one day [2] Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until July 22, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States, with over 70 employees dedicated to serving clients [4]

Financial Data and Key Metrics Changes - In 2024, Organon reported full year revenue of $6.4 billion, representing a 3% growth at constant currency, marking consecutive years of constant currency revenue growth across all three franchises [27][28] - The company generated $967 million in free cash flow before one-time costs, aligning with expectations, and improved adjusted EBITDA margin year over year excluding IPR&D [28] Business Line Data and Key Metrics Changes - The women's health franchise grew by 5% year over year at constant currency, driven by strong double-digit performance of Nexplanon, which is on track to exceed $1 billion in 2025 [29] - The biosimilars franchise delivered 12% growth at constant currency, with HEDLEMA being a leading biosimilar by total prescriptions in the US [30] - Established brands grew by 2% year over year at constant currency, marking consecutive years of growth for this franchise [30] Market Data and Key Metrics Changes - The company is navigating the loss of exclusivity for one of its largest products, Adazed, in Europe, which is expected to impact revenue in 2025 [35] - The revenue growth profile is anticipated to be in the low to mid single-digit range on a constant currency basis over the medium term [35] Company Strategy and Development Direction - Organon is focused on delivering long-term shareholder value through a diversified global portfolio and has prioritized capital allocation to reduce debt faster [32] - The company aims to enhance its revenue growth profile through strategic acquisitions and investments in innovation, particularly in women's health [32][39] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's strategy and its ability to weather a volatile macroeconomic environment, emphasizing the importance of deleveraging and improving margins [36][38] - The commitment to women's health remains strong, with ongoing investments in areas of high unmet need, such as endometriosis and migraine treatments [39][40] Other Important Information - The board of directors recommended against a shareholder proposal for a director election resignation guideline, citing existing governance practices [17][22] - The preliminary vote report indicated that 20.9% of total votes cast supported the shareholder proposal, which did not achieve the majority required for approval [22] Q&A Session Summary Question: When can we expect Organon to return to growth? - Management indicated that growth is expected to resume post-2025 as the company navigates the loss of exclusivity for Adazed and anticipates continued uptake in VITAMMA and growth in the biosimilars business [35] Question: What drove the company's recent decision to reduce its dividend payout? - The decision was part of a reset in capital allocation priorities aimed at accelerating deleveraging to strengthen the company's financial position [36] Question: Can Organon improve its margins? Are there opportunities to reduce organizational costs? - Management confirmed a focus on optimizing the cost structure, targeting $200 million in cost savings for 2025, which is expected to annualize to approximately $275 million in 2026 and beyond [37][38] Question: How committed is Organon to its vision of being a leader in women's health? - The company remains committed to improving women's health, emphasizing its unique focus in this area and ongoing investments in relevant therapeutic areas [39][40] Question: How does current executive compensation align with financial results? - Executive compensation is closely tied to performance, with a significant portion being variable and based on measurable outcomes, ensuring alignment with shareholder interests [42][44]

Core Viewpoint - A class action lawsuit has been filed against Organon & Co. for alleged securities fraud and unlawful business practices [2][4]. Group 1: Lawsuit Details - The lawsuit involves claims that Organon and certain officers and/or directors engaged in securities fraud or other unlawful business practices [2]. - Investors who purchased Organon securities during the Class Period have until July 22, 2025, to request to be appointed as Lead Plaintiff [2]. Group 2: Financial Performance - On May 1, 2025, Organon reported a significant reduction in its dividend payout from $0.28 to $0.02, indicating a shift in capital allocation priorities [4]. - Following the announcement of the dividend cut, Organon's stock price dropped by $3.48 per share, or 26.91%, closing at $9.45 per share on the same day [4].

NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Organon & Co. (NYSE: OGN) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Organon you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/organon-co-class-action. Investors have until July 22, 2025, to ask the Court to be appointed to lea ...

Core Viewpoint - A class action securities lawsuit has been filed against Organon & Co. due to alleged securities fraud that negatively impacted investors between October 31, 2024, and April 30, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Organon's management made overly positive statements while concealing material adverse facts about the company's capital allocation priorities, particularly regarding a significant debt reduction strategy following the acquisition of Dermavant [2]. - As a result of these actions, Organon reduced its regular quarterly dividend by 70%, leading to a dramatic decline in stock price from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025, representing a drop of over 27% in just one day [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until July 22, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving in this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, and there is no obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the United States [4].